Efgartigimod is FDA-approved and indicated for treating generalized MG in adults who test positive for antiacetylcholine receptor (AChR) antibodies. In phase 3 trials, treatment with efgartigimod reduced disease burden and improved strength and quality of life in patients with generalized MG across four MG-specific scales. These benefits were observed early and were reproducible and durable.
Efgartigimod is an antibody fragment designed to block the immunoglobulin (Ig) G recycling process and reduce pathogenic IgG antibodies, which most patients with generalized MG have. The agent reduces IgG antibody levels by binding to and blocking the neonatal Fc receptor.
Learn more about efgartigimod.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Myasthenia Gravis Treatments - Medscape - Mar 15, 2022.
Comments